What is HC Wainwright's Forecast for AARD FY2027 Earnings?

Key Points

• HC Wainwright set its FY2027 earnings estimate for Aardvark Therapeutics at ($1.98) per share, which is less negative than the broader consensus estimate of ($3.46) per share.
• The firm kept a Neutral rating on AARD and maintained a $6.00 price target.
• Aardvark recently reported a quarterly loss of ($0.99) EPS, while other analysts remain mixed overall, with the stock currently carrying an average Hold rating and a consensus target price of $16.30.

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Free Report) - Stock analysts at HC Wainwright issued their FY2027 earnings estimates for shares of Aardvark Therapeutics in a note issued to investors on Monday, July 20th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($1.98) per share for the year. HC Wainwright currently has a "Neutral" rating and a $6.00 price target on the stock. The consensus estimate for Aardvark Therapeutics' current full-year earnings is ($3.46) per share.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter.

Several other research firms have also weighed in on AARD. BTIG Research lowered Aardvark Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, May 15th. Weiss Ratings raised Aardvark Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 2nd. Morgan Stanley reaffirmed an "underweight" rating and set a $3.00 target price (down from $7.00) on shares of Aardvark Therapeutics in a report on Friday, May 15th. Finally, B. Riley Financial decreased their price target on Aardvark Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Aardvark Therapeutics currently has an average rating of "Hold" and an average target price of $16.30.

Aardvark Therapeutics Stock Performance

Aardvark Therapeutics stock opened at $5.53 on Tuesday. The firm has a market cap of $121.00 million, a price-to-earnings ratio of -1.72 and a beta of 3.93. Aardvark Therapeutics has a 1 year low of $3.35 and a 1 year high of $17.94. The firm's 50 day moving average price is $4.82 and its two-hundred day moving average price is $7.47.

Institutional Investors Weigh In On Aardvark Therapeutics

Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in Aardvark Therapeutics during the 1st quarter worth approximately $267,000. Bank of New York Mellon Corp raised its stake in Aardvark Therapeutics by 30.8% during the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company's stock valued at $111,000 after purchasing an additional 6,905 shares during the period. XTX Topco Ltd purchased a new stake in shares of Aardvark Therapeutics in the fourth quarter valued at $335,000. Superstring Capital Management LP purchased a new stake in shares of Aardvark Therapeutics in the fourth quarter valued at $912,000. Finally, Millennium Management LLC boosted its position in shares of Aardvark Therapeutics by 51.2% in the fourth quarter. Millennium Management LLC now owns 483,340 shares of the company's stock worth $6,344,000 after buying an additional 163,717 shares during the period.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company's lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.